Psychiatry and Neurology, Neurology · New York, NY
NPI
1245327337
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
710 W 168th St
New York, NY, 10032
Phone (646) 426-3876
Groups this clinician bills Medicare through
Medicare paid, 2024
$123K
1,322 services
Medicare patients, 2024
357
Average age 74
Drug cost, 2024
$10.1M
1,277 prescriptions
Company payments, 2025
$21K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas H Brannagan III was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 369 times for 209 patients. In total Thomas H Brannagan III billed 1,322 services in 33 codes, and Medicare paid $123K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-06.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 369 | 209 | $15.15 | $5,589 |
| 99214 Office E&M - Established | Office | 163 | 117 | $114.56 | $19K |
| 99215 Office E&M - Established | Office | 159 | 124 | $165.62 | $26K |
| 95885 Electrical Nerve Conductivity | Office | 137 | 93 | $58.86 | $8,064 |
| 95886 Electrical Nerve Conductivity | Office | 110 | 87 | $90.74 | $9,981 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 57 | 38 | $30.69 | $1,749 |
| 95913 Electrical Nerve Conductivity | Office | 51 | 50 | $271.85 | $14K |
| 95911 Electrical Nerve Conductivity | Office | 47 | 47 | $199.14 | $9,359 |
| 99213 Office E&M - Established | Office | 43 | 39 | $83.40 | $3,586 |
| 95912 Electrical Nerve Conductivity | Office | 36 | 36 | $235.50 | $8,478 |
| 99205 Office E&M - New | Office | 30 | 30 | $193.01 | $5,790 |
| 95910 Electrical Nerve Conductivity | Office | 19 | 19 | $162.01 | $3,078 |
| 36415 Venipuncture Blood Collection | Office | 15 | 15 | $8.65 | $130 |
| 95909 Electrical Nerve Conductivity | Office | 11 | 11 | $128.67 | $1,415 |
By year: 2022 $129K for 1,094 services; 2023 $127K for 1,073 services; 2024 $123K for 1,322 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 15 | 15 | $8.65 | $130 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas H Brannagan III prescribed most often to Medicare patients was Pregabalin, with 179 prescriptions and refills. In total Thomas H Brannagan III wrote 1,277 Medicare prescriptions that cost $10.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pregabalin Generic | 179 | 243 | 35 | $4,570 |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 142 | 142 | Under 11 | $1.2M |
| Gabapentin Generic | 108 | 228 | 27 | $2,564 |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 106 | 109 | Under 11 | $1.3M |
| Gammaked Immune Globul G/Gly/Iga Avg 46 | 79 | 79 | Under 11 | $1.3M |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | 77 | 77 | Under 11 | $1.0M |
| Lamotrigine Generic | 75 | 187 | 15 | $2,001 |
| Oxcarbazepine Generic | 68 | 125 | 17 | $2,799 |
| Sodium Chloride 0.9 % Sodium Chloride | 57 | 57 | Under 11 | $289 |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 50 | 50 | Under 11 | $422K |
| Duloxetine Hcl Generic | 47 | 113 | 14 | $1,891 |
| Wainua Eplontersen Sodium | 31 | 31 | Under 11 | $1.3M |
| Diphenhydramine Hcl Generic | 28 | 28 | 14 | $166 |
| Vyvgart Hytrulo Efgartigimod-Hyaluronidas-Qvfc | 26 | 26 | Under 11 | $968K |
| Lacosamide Generic | 17 | 19 | Under 11 | $356 |
Brand drugs: 665 claims; generic drugs: 612 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas H Brannagan III $21K ($21K in general payments such as food, travel and fees) from 15 companies. The largest payer was Genzyme Corporation with $8,154.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 1 | $8,154 |
| Grifols USA, LLC | 13 | $7,574 |
| AstraZeneca Pharmaceuticals LP AZN | 19 | $4,199 |
| Argenx US, Inc. ARGX | 7 | $519 |
| Alnylam Pharmaceuticals Inc. ALNY | 10 | $303 |
| Grifols Shared Services North America, Inc. | 1 | $295 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $103 |
| Janssen Biotech, Inc. JNJ | 1 | $42.77 |
| Catalyst Pharmaceuticals, Inc. CPRX | 1 | $36.4 |
| ITF Therapeutics LLC | 1 | $33.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.